Therapy Areas: Vaccines
Dr. Jiong Ma Named to LinKinVax Board Member
5 May 2022 - - France-based clinical-stage biotechnology company LinKinVax has appointed Dr. Jiong Ma as independent board member, the company said.

Dr. Jiong Ma brings over 25 years of experience in investing, building, and scaling technology companies.

Based in the United States, she served as Senior Partner and a member of the investment committee at Braemar Energy Ventures, leading investments in resource efficiency, e-mobility, industrial digitalization, renewable energy, and deep tech.

She is founder and board of director of Chavant Capital acquisition Corp. (NASDAQ: CLAY). Ma serves on the boards Solid Energy Systems (NYSE: SES), Anavex Life Sciences Corp. (NASDAQ: AVXL).

In addition, she is an advisory board member for National Renewable Energy Labs.

Previously, Jiong was an investment professional at 3i, a global private equity firm, where she led investments in technology and media, digital health and cleantech.

Jiong held several senior positions at Lucent Technologies and Bell Labs, responsible for product portfolio strategy, new product launches, and research and product development.

Dr. Ma holds a PhD in Electrical and Computer Engineering from the University of Colorado at Boulder, an MS in Electrical Engineering from Worchester Polytechnic Institute, and a BS in Physics and Electrical Engineering from Lanzhou University in China. She is also a Kauffman Fellow.

Thanks to the potential of its technology platform and the advances in its portfolio, LinKinVax aims to make a decisive contribution to the global public health challenges of infectious diseases and cancer.

LinKinVax's vaccine platform is built around a humanized monoclonal antibody, which is merged with regions of pathogens of interest, targeting the CD40 molecule expressed by dendritic cells, DC, which play a key role in stimulating the immune system.

The results obtained demonstrate the benefits of this strategy owing to the small quantity of antigens required to activate the immune system, with or without an adjuvant, and its ability to trigger a lasting cellular and humoral and immune response.

The platform also benefits from the experience and safety profile of the protein-based vaccines that have been widely used for over 30 years now.

Three products are in or about to enter clinical trials: a prophylactic vaccine for HIV, currently in phase I led by Inserm/ANRS-EID), a SARS-CoV-2 vaccine covering variants of interest, and a therapeutic vaccine for human papillomavirus-related cancers.